Found: 20
Select item for more details and to access through your institution.
Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 5, p. 1046, doi. 10.1038/leu.2011.297
- By:
- Publication type:
- Article
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
- Published in:
- Leukemia (08876924), 2011, v. 25, n. 12, p. 1877, doi. 10.1038/leu.2011.165
- By:
- Publication type:
- Article
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.
- Published in:
- Leukemia (08876924), 2011, v. 25, n. 9, p. 1502, doi. 10.1038/leu.2011.112
- By:
- Publication type:
- Article
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
- Published in:
- Leukemia (08876924), 2010, v. 24, n. 7, p. 1343, doi. 10.1038/leu.2010.108
- By:
- Publication type:
- Article
Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2005, v. 130, n. 1, p. 36, doi. 10.1111/j.1365-2141.2005.05548.x
- By:
- Publication type:
- Article
Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
- Published in:
- Clinical & Experimental Immunology, 2016, v. 183, n. 1, p. 90, doi. 10.1111/cei.12697
- By:
- Publication type:
- Article
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 584, doi. 10.1002/hon.3164_438
- By:
- Publication type:
- Article
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 472, doi. 10.1002/hon.3164_347
- By:
- Publication type:
- Article
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 430, doi. 10.1002/hon.3164_317
- By:
- Publication type:
- Article
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 344, doi. 10.1002/hon.3164_246
- By:
- Publication type:
- Article
Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 341, doi. 10.1002/hon.3164_244
- By:
- Publication type:
- Article
IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.98_2880
- By:
- Publication type:
- Article
PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.97_2880
- By:
- Publication type:
- Article
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.89_2880
- By:
- Publication type:
- Article
INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.83_2880
- By:
- Publication type:
- Article
INDUCTION R<sup>2</sup> FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.63_2879
- By:
- Publication type:
- Article
INDUCTION R<sup>2</sup> FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.23_2881
- By:
- Publication type:
- Article
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.173_2880
- By:
- Publication type:
- Article
BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.166_2880
- By:
- Publication type:
- Article
FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.149_2880
- By:
- Publication type:
- Article